Document is current
Any future updates will be listed below
-
Authors
Miller, Alex B. https://orcid.org/0000-0002-1847-4891
Rodriguez, Felicia H.
Langenbucher, Adam
Lin, Lin
Bray, Christina
Duquette, Sarah
Zhang, Ye
Goulet, Dan
Lane, Andrew A. https://orcid.org/0000-0001-7380-0226
Weinstock, David M. https://orcid.org/0000-0002-8724-3907
Hemann, Michael T. https://orcid.org/0000-0001-6776-2163
Manalis, Scott R. https://orcid.org/0000-0001-5223-9433
-
Funding
Funding for this research was provided by:
Virginia and D.K. Ludwig Fund for Cancer Research
EIF | Stand Up To Cancer (3.1416)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01 CA248384)
- License Information
-
More Information
Article History
Received: 13 September 2023
Accepted: 10 April 2024
First Online: 20 April 2024
Competing interests
: The authors declare the following competing interests: A.B.M. is an employee of RA Capital Management. D.R.G. is an employee of Vor Biopharma Inc. D.M.W. is an employee of Merck and Co., owns equity in Merck and Co., Bantam, Ajax, and Travera, received consulting fees from Astra Zeneca, Secura, Novartis, and Roche/Genentech, and received research support from Daiichi Sankyo, Astra Zeneca, Verastem, Abbvie, Novartis, Abcura, and Surface Oncology. A.A.L. received research funding from Abbvie and Stemline therapeutics, and consulting fees from Cimeio Therapeutics, IDRx, Jnana Therapeutics, ProteinQure, and Qiagen, and has equity as an advisor for Medzown. S.R.M. owns equity in Travera and Affinity Biosensors. All other authors declare no competing interests.
